Literature DB >> 27245757

Promoter methylation and mRNA expression of HLA-G in relation to HLA-G protein expression in colorectal cancer.

Marloes Swets1, Lina Seneby2, Arnoud Boot3, Tom van Wezel3, Hans Gelderblom4, Cornelis J H van de Velde2, Peter J van den Elsen5, Peter J K Kuppen6.   

Abstract

Expression of human leukocyte antigen-G (HLA-G) is a suggested mechanism used by tumor cells to escape from host immune recognition and destruction. Advances in the field have made it evident that HLA-G is expressed in different types of malignancies including colorectal cancer (CRC). We analyzed HLA-G expression in 21 low passage CRC cell lines. The level of DNA methylation of the HLA-G gene and the presence of mRNA encoding HLA-G was measured. Moreover, HLA-G protein expression was determined by flow cytometry and immunohistochemistry (IHC). IHC was performed with three different monoclonal antibodies (mAbs) (4H84, MEM-G/1 and MEM-G/2). In addition, HLA-G protein expression was measured in matching primary tumor tissues. RNA analysis using RT-PCR followed by sequencing in 6 samples indicated strong homology of the PCR product with HLA-G3 in 5 samples. In accordance, in none of the cell lines, HLA-G1 expression was detected by flow-cytometry. Furthermore, no association between HLA-G DNA methylation patterns and HLA-G mRNA expression was observed. In addition, different immunohistochemical staining profiles among various anti-HLA-G mAbs were observed. In conclusion, the results of this study show that the HLA-G3 isoform was expressed in some of the CRC cell lines irrespective of the level of DNA methylation of HLA-G.
Copyright © 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer cell lines; Colorectal cancer; DNA methylation; HLA-G

Mesh:

Substances:

Year:  2016        PMID: 27245757     DOI: 10.1016/j.humimm.2016.05.023

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

Review 1.  Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications.

Authors:  Daniel Desaulniers; Paule Vasseur; Abigail Jacobs; M Cecilia Aguila; Norman Ertych; Miriam N Jacobs
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

2.  HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.

Authors:  Marica Garziera; Saverio Virdone; Elena De Mattia; Lucia Scarabel; Erika Cecchin; Jerry Polesel; Mario D'Andrea; Nicoletta Pella; Angela Buonadonna; Adolfo Favaretto; Giuseppe Toffoli
Journal:  Int J Mol Sci       Date:  2017-06-27       Impact factor: 5.923

Review 3.  HLA-G: A New Immune Checkpoint in Cancer?

Authors:  Daniëlle Krijgsman; Jessica Roelands; Wouter Hendrickx; Davide Bedognetti; Peter J K Kuppen
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

4.  Characterization of HLA-G Regulation and HLA Expression in Breast Cancer and Malignant Melanoma Cell Lines upon IFN-γ Stimulation and Inhibition of DNA Methylation.

Authors:  Nanna Jørgensen; Abid Sayed; Helene Bjerregaard Jeppesen; Gry Persson; Iben Weisdorf; Tina Funck; Thomas Vauvert Faurschou Hviid
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

Review 5.  Role of immune escape in different digestive tumours.

Authors:  Xin-Zhu Du; Bin Wen; Lin Liu; Ying-Ting Wei; Kui Zhao
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

6.  Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.

Authors:  Hui-Hui Xu; Jun Gan; Dan-Ping Xu; Lu Li; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.